Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) saw strong trading volume on Monday . 374,419 shares changed hands during trading, an increase of 62% from the previous session’s volume of 231,494 shares.The stock last traded at $86.27 and had previously closed at $86.05.

Several equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research report on Monday, May 2nd. Jefferies Group increased their price objective on shares of Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, July 29th. Barclays PLC increased their price objective on shares of Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. JPMorgan Chase & Co. initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $85.00 target price on shares of Integra LifeSciences Holdings Corp. in a research note on Friday, June 24th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Integra LifeSciences Holdings Corp. presently has an average rating of “Buy” and an average target price of $82.88.

The company has a market cap of $3.22 billion and a P/E ratio of 356.49. The company has a 50-day moving average of $82.92 and a 200-day moving average of $72.86.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.76 by $0.03. During the same period in the previous year, the firm posted $0.79 EPS. The company earned $249.30 million during the quarter, compared to analysts’ expectations of $243.17 million. Integra LifeSciences Holdings Corp.’s revenue was up 17.2% compared to the same quarter last year. On average, analysts forecast that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current fiscal year.

In other Integra LifeSciences Holdings Corp. news, Director Raymond G. Murphy sold 2,610 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $84.83, for a total transaction of $221,406.30. Following the sale, the director now owns 33,057 shares of the company’s stock, valued at approximately $2,804,225.31. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Richard D. Gorelick sold 4,000 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Monday, August 1st. The stock was sold at an average price of $84.60, for a total transaction of $338,400.00. Following the sale, the vice president now directly owns 9,702 shares in the company, valued at approximately $820,789.20. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Integra LifeSciences Holdings Corp. stock. Principal Financial Group Inc. raised its stake in Integra LifeSciences Holdings Corp. (NASDAQ:IART) by 7.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 196,763 shares of the company’s stock after buying an additional 12,904 shares during the period. Principal Financial Group Inc. owned about 0.53% of Integra LifeSciences Holdings Corp. worth $13,337,000 as of its most recent filing with the SEC.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.